Nurix Therapeutics is a biopharmaceutical company that seeks to develop and commercialize small molecule therapies for the treatment of cancer and immune disorders. The company is focused on developing a range of orally available inhibitors and degraders for the treatment of relapsed or refractory B-cell malignancies, autoimmune diseases, and immuno-oncology indications. Nurix Therapeutics has established strategic collaboration agreements with Gilead Sciences and Sanofi S.A to tackle challenging diseases for patients.